✦ LIBER ✦

Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer

✍ Scribed by Jonat, W

Book ID: 109838715
Publisher: Nature Publishing Group
Year: 1998
Tongue: English
Weight: 579 KB
Volume: 78
Category: Article
ISSN: 0007-0920
DOI: 10.1038/bjc.1998.754

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Luteinizing hormone-releasing hormone an

Luteinizing hormone-releasing hormone analogue: leuprorelin acetate for the prevention of menstrual bleeding in premenopausal women undergoing stem cell transplantation

✍ Chiusolo, P; Salutari, P; Sica, S; Scirpa, P; Laurenti, L; Piccirillo, N; Leone, 📂 Article 📅 1998 🏛 Nature Publishing Group 🌐 English ⚖ 33 KB

Optimal adjuvant hormonal therapy in pos

Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: have we answered the question?

✍ Alfonso Sánchez-Muñz; Nuria Ribelles; Emilio Alba 📂 Article 📅 2010 🏛 Springer Milan 🌐 Spanish ⚖ 561 KB

Gonadotropin-releasing hormone analogues

Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma

✍ Francesco Recchia; Gaetano Saggio; Giovanna Amiconi; Anna Di Blasio; Alisia Cest 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB 👁 1 views

## Abstract ## BACKGROUND The objective of the current study was a retrospective evaluation of 100 consecutive premenopausal women with high‐risk, early breast carcinoma who received a gonadotropin‐releasing hormone (Gn‐RH) analogue as ovarian protection during adjuvant chemotherapy. ## METHODS

Optimizing the use of aromatase inhibito

Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer: current and future prospects

✍ Walter Jonat; Felix Hilpert 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 412 KB

Cost-effectiveness analysis of anastrozo

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial

✍ Gershon Y. Locker; Robert Mansel; David Cella; Deborah Dobrez; Sonja Sorensen; S 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 267 KB